Association of plasminogen activator inhibitor-1 and tissue plasminogen activator with type 2 diabetes and metabolic syndrome in Malaysian subjects

被引:36
|
作者
Al-Hamodi, Zaid [1 ]
Ismail, Ikram S. [2 ]
Saif-Ali, Riyadh [1 ,3 ]
Ahmed, Khaled A. [4 ]
Muniandy, Sekaran [1 ]
机构
[1] Univ Malaya, Fac Med, Dept Mol Med, Kuala Lumpur 50603, Malaysia
[2] Univ Malaya, Med Ctr, Dept Med, Kuala Lumpur 50603, Malaysia
[3] Sanaa Univ, Fac Med, Dept Biochem, Sanaa, Yemen
[4] Ibb Univ, Fac Dent, Ibb, Yemen
来源
关键词
CORONARY-HEART-DISEASE; INSULIN-RESISTANCE SYNDROME; MYOCARDIAL-INFARCTION; ARTERY-DISEASE; RISK-FACTORS; FIBRINOLYTIC SYSTEM; PREDICTIVE-VALUE; PLASMA; OBESITY; INFLAMMATION;
D O I
10.1186/1475-2840-10-23
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Increased plasma plasminogen activator inhibitor-1 (PAI-1) activity and decreased tissue plasminogen activator (tPA) activity could be considered a true component of the metabolic syndrome (MetS) associated with an increased risk of developing cardiovascular diseases (CVD) and fibrinolytic abnormalities. The aim of this study was to investigate the association of tPA and its inhibitor PAI-1 with type 2 diabetes (T2D) and MetS and interrelationship between PAI-1 and tPA activities and antigens in Malaysian T2D and normal subjects. Methods: The plasma activities and antigens of PAI-1 and tPA and the levels of the tPA/PAI-1 complex as well as serum insulin, parameter of the coronary risk panel and plasma glucose at fasting state were studied in 303 T2D subjects (227 with MetS and 76 without MetS), 131 normal non-diabetic non-metabolic subjects and 101 nondiabetic MetS subjects. Results: The PAI-1 activity was higher in subjects with T2D with MetS (P = 9.8 x 10(-19)) and non-diabetic subjects with MetS (P = 3.0 x 10(-15)), whereas the tPA activity was lower in T2D with MetS (P = 0.003) as compare to normal subjects. Plasma tPA antigen levels were higher in subjects with T2D with MetS (P = 8.9 x 10(-24)), T2D without MetS (P = 1.3 x 10(-13)) and non-diabetic MetS subjects (P = 0.002). The activity and antigen of PAI-1 in normal subjects were related to insulin resistance (P = 2.2 x 10(-4); 0.007). Additionally, the PAI-1 activity was associated with an increased waist circumference (P = 2.2 x 10(-4)) and decreased HDL-c (P = 0.005), whereas the tPA activity was associated with decreased FBG (P = 0.028). The highest correlation was between PAI-1 activity and its antigen (R-2 = 0.695, P = 1.1 x 10(-36)) in diabetic subjects. The tPA activity negatively correlated with its antigen (R-2 = -0.444, P = 7.7 x 10(-13)) in normal subjects and with the PAI-1 activity and antigen (R-2 = -0.319, P = 9.9 x 10(-12); R2 = -0.228, P = 3.4 x 10(-6)) in diabetic subjects. Conclusions: PAI-1 and tPA activities and antigens were associated with diabetes and MetS parameters in Malaysian subjects.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Association of plasminogen activator inhibitor-1 and tissue plasminogen activator with type 2 diabetes and metabolic syndrome in Malaysian subjects
    Zaid Al-Hamodi
    Ikram S Ismail
    Riyadh Saif-Ali
    Khaled A Ahmed
    Sekaran Muniandy
    Cardiovascular Diabetology, 10
  • [2] Effect of Plasminogen Activator Inhibitor-1 and Tissue Plasminogen Activator Polymorphisms on Susceptibility to Type 2 Diabetes in Malaysian Subjects
    Al-Hamodi, Zaid
    Saif-Ali, Riyadh
    Ismail, Ikram S.
    Ahmed, Khaled A.
    Muniandy, Sekaran
    JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY, 2012,
  • [3] Impact of Ethnicity on the Association of Plasminogen Activator Inhibitor-1 and Tissue Plasminogen Activator Polymorphisms with Type 2 Diabetes Mellitus
    Al-Hamodi, Z.
    Saif-Ali, R.
    Ismail, I. S.
    Poh, R.
    Ahmed, R. H.
    Muniandy, S.
    PUBLIC HEALTH GENOMICS, 2015, 18 : 30 - 30
  • [4] Plasminogen Activator Inhibitor-1 and Tissue-Plasminogen Activator in Minority Adolescents with Type 2 Diabetes and Obesity
    Vatcharapan Umpaichitra
    M Mahmood Hussain
    Salvador Castells
    Pediatric Research, 2005, 58 : 483 - 487
  • [5] Plasminogen activator inhibitor-1 and tissue-plasminogen activator in minority adolescents with type 2 diabetes and obesity
    Umpaichitra, V
    Hussain, MM
    Castells, S
    PEDIATRIC RESEARCH, 2005, 58 (03) : 483 - 487
  • [6] Tissue plasminogen activator, plasminogen activator inhibitor-1, and tissue plasminogen activator/plasminogen activator inhibitor-1 complex as risk factors for the development of a first stroke
    Johansson, L
    Jansson, JH
    Boman, K
    Nilsson, TK
    Stegmayr, B
    Hallmans, G
    STROKE, 2000, 31 (01) : 26 - 32
  • [7] Genetic Architecture of Tissue-Type Plasminogen Activator and Plasminogen Activator Inhibitor-1
    Asselbergs, Folkert W.
    Pattin, Kristine
    Snieder, Harold
    Hillege, Hans L.
    van Gilst, Wiek H.
    Moore, Jason H.
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2008, 34 (06): : 562 - 568
  • [8] Tissue plasminogen activator and plasminogen activator inhibitor-1 in stroke patients
    Lindgren, A
    Lindoff, C
    Norrving, B
    Astedt, B
    Johansson, BB
    STROKE, 1996, 27 (06) : 1066 - 1071
  • [9] Tissue plasminogen activator and plasminogen activator inhibitor-1 promote tissue integration of biomaterial
    Hessenauer, M.
    Reichel, C. A.
    Berghaus, A.
    Strieth, S.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2013, 43 : 8 - 8
  • [10] Effect of Tisseel® on expression of tissue plasminogen activator and plasminogen activator inhibitor-1
    Diamond, MP
    Kruger, M
    Saed, GM
    FERTILITY AND STERILITY, 2004, 81 (06) : 1657 - 1664